{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:12:14Z","timestamp":1761718334700},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.ejps.2014.08.003","type":"journal-article","created":{"date-parts":[[2014,8,23]],"date-time":"2014-08-23T05:52:01Z","timestamp":1408773121000},"page":"37-43","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Application of the BCS biowaiver approach to assessing bioequivalence of orally disintegrating tablets with immediate release formulations"],"prefix":"10.1016","volume":"64","author":[{"given":"Asami","family":"Ono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohiko","family":"Sugano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2014.08.003_b0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2014.08.003_b0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0928-0987(99)00076-7","article-title":"The biopharmaceutics classification system (BCS): class III drugs \u2014 better candidates for BA\/BE waiver?","volume":"9","author":"Blume","year":"1999","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2014.08.003_b0015","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2174\/138920008786485155","article-title":"Using measured pKa, LogP and solubility to investigate supersaturation and predict BCS class","volume":"9","author":"Box","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2014.08.003_b0020","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1002\/jps.22217","article-title":"The developability classification system: application of biopharmaceutics concepts to formulation development","volume":"99","author":"Butler","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2014.08.003_b0030","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ejps.2004.03.016","article-title":"Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet","volume":"22","author":"Cheng","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2014.08.003_b0035","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1023\/A:1011981317451","article-title":"Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats","volume":"15","author":"Chiou","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2014.08.003_b0040","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1208\/s12248-008-9036-5","article-title":"Application of the biopharmaceutical classification system in clinical drug development\u2014an industrial view","volume":"10","author":"Cook","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2014.08.003_b0045","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1021\/mp1001747","article-title":"Impact of biopharmaceutics classification system-based biowaivers","volume":"7","author":"Cook","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2014.08.003_b0050","unstructured":"CPMP, 2010. Guideline on the Investigation of Bioequivalence. CPMP\/EWP\/QWP\/1401\/98."},{"key":"10.1016\/j.ejps.2014.08.003_b0055","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1021\/mp100175a","article-title":"High-permeability criterion for BCS classification: segmental\/pH dependent permeability considerations","volume":"7","author":"Dahan","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2014.08.003_b0060","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2174\/138920010794328913","article-title":"Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the \u201cAdvanced Dissolution, Absorption, Metabolism (ADAM)\u201d model","volume":"11","author":"Darwich","year":"2010","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2014.08.003_b0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejps.2008.06.015","article-title":"Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2","volume":"35","author":"del Amo","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2014.08.003_b0070","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1208\/s12248-012-9333-x","article-title":"An investigation into the utility of a multi-compartmental, dynamic, system of the upper gastrointestinal tract to support formulation development and establish bioequivalence of poorly soluble drugs","volume":"14","author":"Dickinson","year":"2012","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2014.08.003_b0075","unstructured":"Droxidopa, 2013. Drug Information from the manufacture. <http:\/\/www.info.pmda.go.jp\/go\/interview\/2\/400093_1169006C1039_2_008_1F>."},{"key":"10.1016\/j.ejps.2014.08.003_b0080","unstructured":"European Directorate for the Quality of Medicines, 2009. European Pharmacopoeia 6th edition."},{"key":"10.1016\/j.ejps.2014.08.003_b0085","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1211\/jpp.59.6.0001","article-title":"Evaluation and suggested improvements of the biopharmaceutics classification system BCS","volume":"59","author":"Fagerholm","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2014.08.003_b0090","unstructured":"Famotidine, 2014. Drug Information from the manufacture. <http:\/\/www.info.pmda.go.jp\/go\/interview\/1\/800126_2325003F1024_1_1F>."},{"key":"10.1016\/j.ejps.2014.08.003_b0095","unstructured":"FDA, 2000. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. FDA Guidance for Industry."},{"key":"10.1016\/j.ejps.2014.08.003_b0100","unstructured":"FDA, 2008. Orally Disintegrating Tablets."},{"key":"10.1016\/j.ejps.2014.08.003_b0105","unstructured":"Fexofenadine, 2013. Drug Information from the manufacture. <http:\/\/www.info.pmda.go.jp\/go\/interview\/1\/780069_4490023F1024_1_020_1F>."},{"key":"10.1016\/j.ejps.2014.08.003_b0110","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1007\/s11095-012-0759-8","article-title":"PH-Induced precipitation behavior of weakly basic compounds: determination of extent and duration of supersaturation using potentiometric titration and correlation to solid state properties","volume":"29","author":"Hsieh","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2014.08.003_b0120","unstructured":"Hydrochlorothiazide, 2014. Drug Information from the manufacture. <http:\/\/www.info.pmda.go.jp\/go\/interview\/1\/650168_2149113F1027_1_144_1F>."},{"key":"10.1016\/j.ejps.2014.08.003_b0125","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00003088-200645040-00004","article-title":"Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products","volume":"45","author":"Jantratid","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2014.08.003_b0130","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ejps.2009.03.015","article-title":"Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form","volume":"37","author":"Jantratid","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2014.08.003_b0135","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/mp034006h","article-title":"Molecular properties of WHO essential drugs and provisional biopharmaceutical classification","volume":"1","author":"Kasim","year":"2003","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2014.08.003_b0140","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1208\/s12249-008-9071-7","article-title":"Effect of drug lipophilicity and ionization on permeability across the buccal mucosa: a technical note","volume":"9","author":"Kokate","year":"2008","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejps.2014.08.003_b0145","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s11095-009-9831-4","article-title":"In silico prediction of drug permeability across buccal mucosa","volume":"26","author":"Kokate","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2014.08.003_b0150","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejps.2006.10.011","article-title":"Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates","volume":"30","author":"Kortejarvi","year":"2007","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2014.08.003_b0155","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ejps.2013.08.024","article-title":"In vitro models for the prediction of in vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2014.08.003_b0160","doi-asserted-by":"crossref","first-page":"14","DOI":"10.14227\/DT190412P14","article-title":"A formulation case study comparing the dynamic gastric model with conventional dissolution methods","volume":"19","author":"Mann","year":"2012","journal-title":"Dissolution Technol."},{"key":"10.1016\/j.ejps.2014.08.003_b0165","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1021\/mp1001203","article-title":"Dynamic dissolution: a step closer to predictive dissolution testing?","volume":"7","author":"McAllister","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2014.08.003_b0170","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1081\/DDC-120028713","article-title":"Biopharmaceutics classification by high throughput solubility assay and PAMPA","volume":"30","author":"Obata","year":"2004","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2014.08.003_b0175","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1023\/A:1018947113238","article-title":"Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model","volume":"10","author":"Oh","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2014.08.003_b0180","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejpb.2008.10.019","article-title":"Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products","volume":"72","author":"Okumu","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2014.08.003_b0185","unstructured":"Olopatadine, 2013. Drug Information from the manufacture. <http:\/\/www.info.pmda.go.jp\/go\/interview\/1\/230124_4490025F3026_1_004_1F>."},{"key":"10.1016\/j.ejps.2014.08.003_b0190","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1208\/s12248-008-9040-9","article-title":"Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond","volume":"10","author":"Polli","year":"2008","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2014.08.003_b0195","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1365-2125.2010.03757.x","article-title":"Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the biopharmaceutic classification system","volume":"70","author":"Ramirez","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2014.08.003_b0205","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1208\/s12248-008-9030-y","article-title":"Scientific perspectives on extending the provision for waivers of in vivo bioavailability and bioequivalence studies for drug products containing high solubility-low permeability drugs (BCS-Class 3)","volume":"10","author":"Stavchansky","year":"2008","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2014.08.003_b0210","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1273\/cbij.9.75","article-title":"Fraction of dose absorbed calculation: comparison between analytical solution based on one compartment steady state approximation and dynamic seven compartment model","volume":"9","author":"Sugano","year":"2009","journal-title":"CBI J."},{"key":"10.1016\/j.ejps.2014.08.003_b0215","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1517\/17425250902835506","article-title":"Introduction to computational oral absorption simulation","volume":"5","author":"Sugano","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejps.2014.08.003_b0220","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijpharm.2010.11.049","article-title":"Fraction of a dose absorbed estimation for structurally diverse low solubility compounds","volume":"405","author":"Sugano","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2014.08.003_b0225","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2133\/dmpk.22.225","article-title":"Solubility and dissolution profile assessment in drug discovery","volume":"22","author":"Sugano","year":"2007","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejps.2014.08.003_b0230","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejps.2010.03.011","article-title":"Prediction of food effect by bile micelles on oral drug absorption considering free fraction in intestinal fluid","volume":"40","author":"Sugano","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2014.08.003_b0235","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/mp0600182","article-title":"A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan","volume":"3","author":"Takagi","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2014.08.003_b0240","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1007\/s11095-008-9637-9","article-title":"Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation","volume":"25","author":"Takano","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2014.08.003_b0245","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1365-2125.2003.01722.x","article-title":"The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique","volume":"55","author":"Tannergren","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2014.08.003_b0250","unstructured":"Tartirelin, 2013. Drug Information from the manufacture. <http:\/\/www.info.pmda.go.jp\/go\/interview\/1\/400315_1190014F2021_1_050_1F>."},{"key":"10.1016\/j.ejps.2014.08.003_b0255","unstructured":"The Ministry of Health, Labour and Welfare, 2011. The Japanese Pharmacopoeia 16th edition."},{"key":"10.1016\/j.ejps.2014.08.003_b0260","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1208\/s12248-008-9023-x","article-title":"Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds","volume":"10","author":"Tubic-Grozdanis","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2014.08.003_b0265","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/mp100053q","article-title":"The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation","volume":"7","author":"Tume","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2014.08.003_b0275","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/bdd.2510070602","article-title":"Pharmacokinetics of the thiazide diuretics","volume":"7","author":"Welling","year":"1986","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2014.08.003_b0280","unstructured":"WHO, 2006. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. WHO Technical Report Series, No. 937, Annex 8."},{"key":"10.1016\/j.ejps.2014.08.003_b0285","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: transport\/absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2014.08.003_b0290","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1021\/mp800140m","article-title":"Analysis of risk factors in human bioequivalence study that incur bioinequivalence of oral drug products","volume":"6","author":"Yamashita","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2014.08.003_b0295","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1023\/B:PHAM.0000016242.48642.71","article-title":"The \u201chigh solubility\u201d definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs","volume":"21","author":"Yazdanian","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2014.08.003_b0300","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0378-5173(99)00147-7","article-title":"A compartmental absorption and transit model for estimating oral drug absorption","volume":"186","author":"Yu","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2014.08.003_b0305","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0169-409X(96)00009-9","article-title":"Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption","volume":"19","author":"Yu","year":"1996","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2014.08.003_b0310","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1023\/A:1016473601633","article-title":"Biopharmaceutics classification system: the scientific basis for biowaiver extensions","volume":"19","author":"Yu","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2014.08.003_b0315","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1021\/mp100124f","article-title":"A modified physiological BCS for prediction of intestinal absorption in drug discovery","volume":"7","author":"Zaki","year":"2010","journal-title":"Mol. Pharm."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098714003121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098714003121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T10:33:07Z","timestamp":1538303587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098714003121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":59,"alternative-id":["S0928098714003121"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2014.08.003","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of the BCS biowaiver approach to assessing bioequivalence of orally disintegrating tablets with immediate release formulations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2014.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}